US Patent Issued to Alnylam Pharmaceuticals on Feb. 10 for "Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,545,914, issued on Feb. 10, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof" was invented by Lucas D. BonDurant (Brookline, Mass.), Mark K. Schlegel (Boston), Jeffrey Zuber (Somerville, Mass.), Lauren Blair Woods (Sharon, Mass.) and Tyler Chickering (Needham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to metho...